| Document |
Document Title |
|
WO/2021/150603A1 |
Disclosed is a compound of formula (I) in which R1, R2, R3, X1, X2, X2', X3, X4, ring A, m, n, and o are as described herein. The compound of formula (I) is useful for treating a disorder associated with androgen receptor malfunction, su...
|
|
WO/2021/149767A1 |
Provided are: a heterocyclic derivative and/or a pharmaceutically acceptable salt thereof that can serve as a therapeutic agent and/or a prophylactic agent for a disease in which the sodium channel (Nav) is involved and for various centr...
|
|
WO/2021/143677A1 |
The invention belongs to the technical field of pesticides, and specifically relates to a fused ring substituted aromatic compound and a preparation method therefor, a herbicidal composition, and the use thereof. The fused ring substitut...
|
|
WO/2021/143823A1 |
The present invention relates to a pyridine or pyrimidine derivative, and a preparation method therefor and pharmaceutical use thereof. Specifically, the present invention relates to a pyridine or pyrimidine derivative represented by gen...
|
|
WO/2021/146543A1 |
Provided herein are compounds having the following structural formula, wherein values for the variables are as described herein. Also provided are pharmaceutical compositions of the compounds, as well as methods of using the compounds to...
|
|
WO/2021/143927A1 |
A compound used as a BCR-ABL inhibitor in the field of pharmaceutical chemistry, that is, a compound represented by formula (I), or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical compositi...
|
|
WO/2021/144796A1 |
The present disclosure relates to a solid state form of Pyroxasulfone, processes for preparation thereof and agrochemical compositions thereof.
|
|
WO/2021/143680A1 |
The present invention relates to a heteroaryl derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a heteroaryl derivative as represented by general formula (AI...
|
|
WO/2021/139599A1 |
The present invention relates to the technical field of drugs, and in particular, to an RORγt inhibitor, a preparation method therefor and use thereof. The present invention also relates to a pharmaceutical composition of the compound, ...
|
|
WO/2021/142006A1 |
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
|
|
WO/2021/139498A1 |
The present invention belongs to the technical field of pesticides, and specifically relates to an isoxazoline oxime carboxylate compound, a preparation method therefor, and a herbicidal composition and a use thereof. The isoxazoline oxi...
|
|
WO/2021/139595A1 |
The present invention relates to the technical field of medicines, in particular to a RORγt inhibitor as well as a preparation method therefor and uses thereof, and also relates to a pharmaceutical composition comprising the compound, a...
|
|
WO/2021/141041A1 |
Provided is a therapeutic agent and/or prophylactic agent for tauopathies that is based on the activation of voltage-gated sodium channels (Nav). The therapeutic agent and/or prophylactic agent for tauopathies has an Nav activator as an ...
|
|
WO/2021/138391A1 |
Disclosed herein are indazole compounds and methods of treating diseases and/or conditions (e.g., cancer) with the indazole compounds disclosed herein.
|
|
WO/2021/136429A1 |
Disclosed is a benzopyrazole compound. Specifically disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/138434A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2021/136333A1 |
The present invention relates to a method for preparing a coumarin compound, the 3 position of which is substituted with an amidoalkyl, and related intermediates thereof. The method includes: step (A): reacting a compound of formula (VI)...
|
|
WO/2021/135181A1 |
The present application provides a nitrogen-containing compound, an organic electroluminescent device and an electronic device, belonging to the technical field of organic materials. The nitrogen-containing compound of the present applic...
|
|
WO/2021/135035A1 |
The present invention relates to a high-performance sky-blue thermally activated delayed fluorescent material, and a preparation method therefor and an application thereof. According to the present invention, the problems in the prior ar...
|
|
WO/2021/132311A1 |
The present invention relates: to a compound represented by formula (1), the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In...
|
|
WO/2021/130257A1 |
The present invention relates to dihydro‐cyclopenta‐isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergi...
|
|
WO/2021/129102A1 |
Disclosed are a heterocyclic compound, a synthesis method therefor, an organic electroluminescent device and an electronic apparatus. The heterocyclic compound has a chemical structural formula as shown in formula 1, wherein M is selecte...
|
|
WO/2021/128764A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic device. The structure of the nitrogen-containing compound is as shown in a...
|
|
WO/2021/129824A1 |
The present invention relates to a compound as shown in formula (1) and a preparation method therefor, and use of the compound of formula (1), optical isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereo...
|
|
WO/2021/132895A1 |
Provided is a benzazole derivative which effectively absorbs a high-energy external light source in the UV region and thus minimizes damage to organic materials in an organic electroluminescent device, thereby contributing to a substanti...
|
|
WO/2021/133886A1 |
Provided herein are pharmaceutical combinations, compositions, and methods of using a compound with estrogen receptor (ER) degradation activity, such as a compound of formula (I) or a tautomer, stereoisomer or a mixture of stereoisomers,...
|
|
WO/2021/130260A1 |
The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as al...
|
|
WO/2021/130262A1 |
The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as a...
|
|
WO/2021/133894A1 |
Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R8, R9, R11A, R11B, R12,R1, R11, A1, A2, Q1, Q2, Q3, X, W, and n are as defined herein; pharmaceutical compositions comprisin...
|
|
WO/2021/133035A1 |
The present invention relates to an amino aryl derivative compound, represented by chemical formula (1) and exhibiting the activity of a diacylglycerol acyltransferase 2 (DGAT2) inhibitor, a pharmaceutical composition comprising same as ...
|
|
WO/2021/132577A1 |
Provided are an acylsulfamide compound or a pharmaceutically acceptable salt thereof having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition containing the same, a pharmaceutical use therefor, and the like. The acylsu...
|
|
WO/2021/130259A1 |
The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as ...
|
|
WO/2021/122986A1 |
The present disclosure relates to substituted thiophene carboxamides derivatives, their use for controlling phytopathogenic microorganisms and compositions comprising thereof.
|
|
WO/2021/127643A1 |
Provided herein are compounds identified as inhibitors of HDAC6 activity that can be used to treat various diseases and disorders.
|
|
WO/2021/121261A1 |
Provided is an EGFR kinase inhibitor according to general formula (I) and a pharmaceutical composition containing the inhibitor. The invention can be used to treat diseases related to EGFR kinase, such as cancer. Also provided is a prepa...
|
|
WO/2021/121363A1 |
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
|
|
WO/2021/121396A1 |
Provided is a tricyclic plasma kallikrein inhibitor compound having a novel structure, good activity and high selectivity, which can be widely used in the prevention or treatment of diseases related to a plasma kallikrein activity.
|
|
WO/2021/127188A1 |
The present invention provides compounds of formula (I): which are useful for long-lasting treatment and control of pests, for example fleas and ticks, in companion animals and livestock, and pharmaceutical compositions and methods of us...
|
|
WO/2021/123785A1 |
The invention relates to heterocyclic derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.
|
|
WO/2021/123174A1 |
The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cogni...
|
|
WO/2021/124222A1 |
The present application provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmac...
|
|
WO/2021/127301A1 |
4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarb...
|
|
WO/2021/123051A1 |
The present disclosure relates to substituted thiophene carboxamides derivatives of formula (I) adn (II), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.
|
|
WO/2021/122538A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/119753A1 |
This disclosure relates to compounds of formula (I), which are modulators of STING. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of using compounds of formula (I) in the treatment or prev...
|
|
WO/2021/123266A1 |
The present invention is related to new pyrrole derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to pyrrole derivatives useful for the preparation of a phar...
|
|
WO/2021/123949A1 |
The present invention relates to solid pharmaceutical compositions comprising N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cycloprop
yl)-phenyl]-acetamide or pharmaceutically acceptable salt thereof. The in...
|
|
WO/2021/127302A1 |
2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated...
|
|
WO/2021/124155A1 |
The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their p...
|
|
WO/2021/117759A1 |
Provided is a novel compound having an HDAC2-inhibitory effect. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, the group represented by formula (II) is for...
|
